BigHat Biosciences Secures $120M Series B to Revolutionize AI-Enabled Antibody Therapeutics

BigHat Biosciences, a trailblazer in antibody therapeutic design, is thrilled to announce the successful closing of a $120 million funding round. This significant infusion of capital marks a pivotal milestone for the company as it escalates its mission to improve human health by revolutionizing the way antibody treatments are conceptualized and developed. At the core of BigHat's innovation is its AI-enabled experimental platform, which masterfully integrates high-speed “wet” lab characterization with advanced machine learning algorithms. This convergence of cutting-edge technology and sophisticated data analysis empowers researchers to expedite the antibody engineering process substantially. With these newly acquired funds, BigHat will not only expand its research capabilities but also accelerate the development of next-generation therapeutics that promise safer and more effective treatment options for patients battling some of today’s most challenging diseases. The company’s ambitious vision and robust platform have already captured the attention of distinguished backers, including Section 32, Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors, and Gaingels. Their confidence underscores the transformative potential of BigHat’s approach in reshaping therapeutic discovery. The funding will be strategically deployed to bolster research and development efforts, optimize operational processes, and foster collaborations that further integrate artificial intelligence with the precision of modern biology. As BigHat Biosciences continues to push the boundaries of scientific innovation, this round of investment not only fuels the immediate scaling of its technology but also lays a foundation for groundbreaking advancements that could redefine treatment paradigms and contribute significantly to the future of global healthcare.